The variability of glycated hemoglobin is associated with renal function decline in patients with type 2 diabetes

Chia-Lin Lee, Cheng-Hsu Chen, Ming-Ju Wu and Shang-Feng Tsai

Abstract

Background: The effect of glucose control, especially variability of glycated hemoglobin (HbA1c), on estimated glomerular filtration rate (eGFR) decline in type 2 diabetes is still debatable.

Methods: We used tertiles of coefficient of variation (CV) to determine the variability of HbA1c (HbA1c_CV). Mixed model repeated measures (MMRM) were used to evaluate the annual eGFR decline rate.

Results: In 1383 type 2 diabetic patients, we found the greater the HbA1c_CV, the greater the eGFR decline (p=0.01, −0.99 in low, −1.73 in mid, and −2.53 ml/min/1.73 m²/year in high HbA1c_CV). Regardless of eGFR (≥60 or <60 ml/min/1.73 m²), the same result holds (p=0.019 and p=0.007, respectively). In subgroup analysis of baseline HbA1c (%) (HbA1c <7, 7 ≤ HbA1c <9, and HbA1c ≥9), tertiles of HbA1c_CV showed similar effects on annual decline of eGFR (p=0.193, 0.300, 0.182, respectively), although a trend for a steeper decline in renal function in the highest HbA1c_CV tertile was observed for all HbA1c strata, and even for HbA1c <7%. A similar behavior was observed in patients with macroalbuminuria or normoalbuminuria (p=0.219, and 0.109, respectively), with a significant trend in those with microalbuminuria (p=0.019). Even in patients with HbA1c <7, high HbA1c_CV also predicts rapid eGFR decline. Before macroalbuminuria, minimizing HbA1c_CV also has renal benefit.

Conclusions: HbA1c variability is an independent risk factor for deterioration of renal function. Even with well-controlled HbA1c levels (<7%), patients with high HbA1c_CV still experienced faster eGFR decline. Early minimization of glycemic variability (before macroalbuminuria) can curb deterioration of renal function. Monitoring and lowering of HbA1c_CV is highly recommended for diabetic care.

Keywords: diabetic kidney disease, glomerular filtration rate, glycated hemoglobin, glycemic variability

Introduction

Type 2 diabetes mellitus (DM) is the leading cause of end-stage renal disease (ESRD) with high prevalence.¹ Nearly half of diabetic patients develop chronic kidney disease (CKD) eventually.² Patients with DM-related CKD receiving early renal replacement therapy have outcomes worse than in ESRD related to other causes. Aggressive treatment for DM, while it reduces consequences such as acute myocardial infarction, stroke, amputation, and death from hyperglycemic crisis, does not change DM-related ESRD.³ The reasons for the poor control of diabetic kidney disease (DKD) are related to the involvement of complicated pathophysiological mechanisms that affect nearly all kidney tissues, such as glomeruli, tubules, interstitia, and blood vessels.⁴,⁵
More than 30 years ago, the staging of DKD was first proposed by Mogensen and colleagues. Recently, hyperfiltration has been considered as the most important mechanism in DKD. After hyperfiltration, microalbuminuria occurs, and then proteinuria can be detected, followed by a low estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m² (definition of CKD), and, finally, ESRD. Angiotensin converting enzyme inhibitors (ACEi) and angiotensin-receptor blocker (ARB) comprise the standard medical treatment of DKD, with the benefit of GFR according to RENAAL and IDNT. Nevertheless, the outcome of DKD remains unsatisfactory. Recently, a number of studies have explained the pleotropic effects of new diabetic medications, in addition to their ability to control glucose levels. These studies show evidence of blocking eGFR decline, and, therefore, major shifts in the algorithm of glucose control have been made in treating type 2 DM. All cardiovascular outcome trials (CVOTs) in diabetic populations are designed to have ‘glycemic equipoise’ between treatment and control groups, but modest differences are still detected in glycated hemoglobin (HbA1c). Therefore, renal benefit with reduced decline in GFR may still result in better glycemic control. Despite this, the role of aggressive glycemic control in slowing the progression of DKD remains debatable.

In our previous study, we proposed a new dynamic model linking HbA1c and eGFR, in which HbA1c has dynamic and dual effects on eGFR both cross-sectionally and longitudinally. This new model can explain the discrepancy between glucose control and renal function among many large-scale studies [such as ACCORD (Action to Control Cardiovascular Risk in Diabetes), VADT (Veterans Affairs Diabetes Trial), DCCT (Diabetes Control and Complications), EDIC (Epidemiology of Diabetes Interventions and Complications) study, and UKPDS (UK Prospective Diabetes Study)]. But the exact effect of glycemic control on renal function remains elusive.

In this study, we propose a more available marker to represent glycemic variability [i.e. tertile of coefficient of variation of HbA1c (HbA1c_CV)] to determine the effect of glycemic control on renal function (eGFR decline). Also, we analyzed over 1000 patients in our study to adjust for many confounding variables.

 Patients and methods

Study population and data collection
This cohort study was performed by physicians at a medical center in central Taiwan. Patients were recruited from the outpatient department between June 2006 and December 2006 based on a documented diagnosis of type 2 DM by an endocrinologist. Once enrolled, all patients were followed up for years (at least until December 2011). Their medical records were reviewed, and their clinical data recorded. Baseline variables included age, gender, HbA1c, eGFR, number of oral antidiabetic drugs (OAD), systolic blood pressure (SBP), and diastolic blood pressure (DBP). Any use of insulin, and antihypertensive and antihyperlipidemic medications was also recorded during enrollment. From 2007 to 2010, HbA1C and eGFR were followed up at 12-month intervals. HbA1c was measured with boronate affinity high-performance liquid chromatography (CLC385 TM, Primus, Kansas City, MO, USA). For HbA1c (range 4.2–19.6%), the inter- and intra-assay coefficients of variation were <0.9 (0.73) and <2.9% (1.93%), respectively. The equation of modification of diet in renal disease (MDRD) was used to calculate eGFR: 

$$\text{MDRD} = 186 \times \frac{\text{serum creatinine} \ (\text{mg/dl})^{-1.154 \times \text{years}^{-0.203 \times \text{0.742, if female} \times \text{1.210, if African American}}}}{\begin{cases} 1 & \text{if female} \end{cases}}$$

The MDRD formula was chosen instead of the
Cockcroft and Gault formula due to its superior accuracy in diabetic patients with impaired renal function. Although CKD-EPI (Epidemiology Collaboration) is more accurate than the MDRD equation for patients with eGFR > 60ml/min/1.73 m², the MDRD formula was applied in the Taiwan National Database to evaluate dialysis initiation and CKD prevalence. CKD in the Taiwan National Database to evaluate dialysis initiation and CKD prevalence. CKD was defined as eGFR < 60ml/min/1.73 m². Patients whose baseline eGFR was > 120 ml/min/1.73 m² were excluded. There were no incretin-based medications or sodium-glucose cotransporter 2 inhibitors (SGLT2) for our patients during the period of this study. Our study was approved by the Human Research Review Committee of the Taichung Veterans General Hospital (CE16235A).

Statistical analyses
Descriptive statistics for continuous variables were expressed as means and standard deviation (SD). All reported p-values were two-sided, and considered significant with p < 0.05. Additionally, 95% confidence intervals (CI) were reported. We used coefficient of variation (CV) of HbA1c (HbA1c_CV) to represent its variability. Furthermore, tertiles of HbA1c_HbA1c_CV were used for subsequent subgroup analyses. Mixed model repeated measures (MMRM) were used to evaluate the annual rate of eGFR decline. Each eGFR value was set as the dependent variable, with time set as the independent variable. Changes in the annual rate of eGFR were defined as the β coefficient of time in MMRM. Interactions with β of time, according to gender, and to HbA1c_CV were determined. Subgroup analyses were done according to baseline HbA1c category (%) (HbA1c < 7%, 7% ≤ HbA1c < 9%, and HbA1c ≥ 9%), baseline eGFR status (CKD or not) (eGFR ≥ 60 and eGFR < 60 ml/min/1.73m²), and baseline urinary albumin excretion (UAE) (UAE < 30, 30 ≤ UAE < 300, and UAE ≥ 300 mg/g). For the MMRM, the age-adjusted and multivariable-adjusted models [adjusted for gender, the number of OADs, insulin usage, antihypertensive medication, hyperlipidemia medication, age, baseline HbA1c (%), and SBP] were reported separately. The eGFR trajectories were generated from the adjusted MMRM. Statistical analyses were performed using the Statistical Package for the Social Science (version 15.0; SPSS Inc, Chicago, IL, USA).

Results
We recruited a total of 1383 patients were recruited for this study (Table 1). Most of them (72.6%) received antihypertensive medication. The glucose control outcome was only fair (8.0 ± 1.8%), and BP was under control (132 ± 16 mmHg of SBP, and 76 ± 9.7 mmHg of DBP). The baseline renal function was relatively good, at an eGFR of 63.0 ± 23.8 ml/min/1.73 m².

We evaluated factors associated with the average of annual eGFR adjusted for age and any other variables (age, gender, numbers of OADs, insulin usage, hypertensive medications, hyperlipidemic medications, and SBP). Age and gender were adjusted because they were both confounding factors for eGFR. Medications for hypertension (ACEi or ARB) were also adjusted because of their long-term renal benefits according to RENAAL and IDNT. We also adjusted the usage of statin because of its potential effect on renal function. In the multivariable-adjusted regression model, we evaluated factors associated with changes of renal function change as the result of controlled glucose level (i.e. variability of HbA1c) (Table 2).

Overall, patients experienced 1.70ml/min/1.73 m² of annual decline of eGFR, regardless of gender (p = 0.889). Patients who had a higher HbA1c_CV, they had a more rapid decline of renal function (0.99 ml/min/1.73 m² for low HbA1c_CV, 1.73 ml/min/1.73 m² for middle HbA1c_CV, and 2.53 ml/min/1.73 m² for high HbA1c_CV, p = 0.01). In the subgroup analysis (baseline eGFR ≥ 60 or eGFR < 60 ml/min/1.73 m²), patients with higher HbA1c_HbA1c_CV had a more rapid deterioration of renal function, a phenomenon found in both subgroups (p = 0.019 and p = 0.007, respectively). Comparing groups of different baseline levels of (≥60 or eGFR < 60 ml/min/1.73 m²), HbA1c_CV played a more important role when eGFR was ≥60ml/min/1.73m² (−1.50 versus −0.21, −2.02 versus −1.29, −2.95 versus −1.94). At low baseline eGFR (<60ml/min/1.73m²), patients with aggressive glucose control and low variability of HbA1c showed no significant renal function decline (annual eGFR decline = −0.21 ml/min/1.73m², 95% CI = −1.04 to 0.61). Similarly, poor baseline glucose control (HbA1c < 7%, 7% ≤ HbA1c < 9%, and HbA1c ≥ 9%) had greater functional decline (high HbA1c_CV: −0.51 versus −1.36 versus −1.61; middle HbA1c_CV: −0.89 versus −1.71 versus −1.80; high HbA1c_CV: −2.07 versus −2.95 versus −3.08).
versus −3.32). For those patients with the best glucose control (baseline HbA1c < 7 and low/middle HbA1c_CV), we found no deterioration in their renal function.

In the subgroup analysis of baseline UAE (UAE < 30, 30 ≤ UAE < 300, and UAE ≥ 300 mg/g) (Table 3), patients with poor baseline UAE (mg/g) had a more rapid decline in eGFR (UAE < 30: −0.33
Table 2. Age-adjusted and multivariable-adjusted annual mean changes in eGFR.

| Group                              | Subgroup | Number of patients | Age-adjusted annual decline of eGFR | 95% CI       | Multivariable-adjusted annual decline of eGFR | 95% CI       | p value |
|------------------------------------|----------|--------------------|-------------------------------------|--------------|-----------------------------------------------|--------------|---------|
| Total                              |          |                    |                                     |              |                                               |              |         |
|                                    |          |                    | −1.70***                             | (–2.10, −1.30)| −1.79***                                      | (–2.20, −1.38)|         |
| Male                               |          |                    | −1.57***                             | (–2.11, −1.02)| −1.77***                                      | (–2.34, −1.21)| 0.889   |
| Female                             |          |                    | −1.84***                             | (–2.42, −1.27)| −1.79***                                      | (–2.38, −1.20)|         |
| Tertile of HbA1c_CV                |          | 1194               |                                     |              |                                               |              |         |
| Low                                |          | 397                | −1.17***                             | (–1.85, −0.49)| −0.99*                                        | (–1.67, −0.31)| 0.01    |
| Middle                             |          | 399                | −1.75***                             | (–2.41, −1.09)| −1.73***                                      | (–2.38, −1.08)|         |
| High                               |          | 398                | −2.66***                             | (–3.43, −1.90)| −2.53***                                      | (–3.28, −1.78)|         |
| Baseline eGFR                      |          |                    |                                     |              |                                               |              |         |
| Baseline eGFR ≥ 60                 |          |                    |                                     |              |                                               |              |         |
|                                    |          |                    | Low                                 |              |                                               |              |         |
| Low                                |          | 241                | −1.70***                             | (–2.30, −1.09)| −1.50***                                      | (–2.12, −0.89)| 0.019   |
| Middle                             |          | 241                | −1.98***                             | (–2.60, −1.37)| −2.02***                                      | (–2.64, −1.39)|         |
| High                               |          | 241                | −3.04***                             | (–3.82, −2.27)| −2.95***                                      | (–3.75, −2.16)|         |
| Baseline eGFR < 60                 |          |                    |                                     |              |                                               |              |         |
|                                    |          |                    | Low                                 |              |                                               |              |         |
| Low                                |          | 156                | −0.35                                | (–1.16, −0.46)| −0.21                                         | (–1.04, 0.61)| 0.007   |
| Middle                             |          | 157                | −1.29***                             | (–2.01, −0.58)| −1.29***                                      | (–1.98, −0.59)|         |
| High                               |          | 157                | −1.92***                             | (–2.65, −1.19)| −1.94***                                      | (–2.66, −1.21)|         |
| Baseline HbA1c                     |          |                    |                                     |              |                                               |              |         |
| Baseline HbA1c < 7                 |          |                    |                                     |              |                                               |              |         |
|                                    |          |                    | Low                                 |              |                                               |              |         |
| Low                                |          | 112                | −0.63                                | (–1.93, 0.65)| −0.51                                         | (–1.76, 0.74)| 0.193   |
| Middle                             |          | 113                | −0.77                                | (–2.13, 0.58)| −0.89                                         | (–2.19, 0.40)|         |
| High                               |          | 112                | −1.87*                               | (–3.18, −0.56)| −2.07*                                        | (–3.47, −0.67)|         |
| Baseline HbA1c ≥ 9                 |          |                    |                                     |              |                                               |              |         |
|                                    |          |                    | Low                                 |              |                                               |              |         |
| Low                                |          | 189                | −1.66***                             | (–2.56, −0.76)| −1.36*                                        | (–2.29, −0.43)| 0.300   |
| Middle                             |          | 189                | −1.56***                             | (–2.47, −0.65)| −1.71***                                      | (–2.68, −0.75)|         |
| High                               |          | 189                | −2.72***                             | (–3.73, −1.70)| −2.46***                                      | (–3.43, −1.49)|         |

(Continued)
versus −0.75 versus −2.43; 30 ≤ UAE < 300: −1.33 versus −2.36 versus −3.56; UAE ≥ 300: −1.34 versus −2.36 versus −4.20). In good baseline renal condition (UAE < 30 mg/g and 30 ≤ UAE < 300 mg/g), aggressive glucose control (low HbA1c_CV) did not lead to a decline in renal function (95% CI = −1.11 to 0.43; 95% CI = −1.93 to 0.42). Once macroalbuminuria is reached (UAE > 300 mg/g), aggressive glucose control (low HbA1c_CV) still produced eGFR decline (95% CI = −4.27 to −0.59).

### Discussion

After 2008, the United States Food and Drug Administration (US FDA) regulated all new anti-diabetic agents used in CVOTs to ensure consideration of ensure their safety in case of CV disease. Those prespecified CVOTs usually set albuminuria or eGFR as their secondary outcome. Studies on SGLT2i seemed to support renal benefits, including albuminuria and eGFR as their secondary outcome. Studies on SGLT2i supported renal benefits, including albuminuria and eGFR. On the other hand, a number of recent studies (including EMPA-REG, DECLARE-TIMI 58, CANVAS, and CREDENCE) support the pleiotropic effects of new diabetic medications, in addition to their ability to control glucose levels. These studies reported a blockade of eGFR decline, and, therefore, the ADA, the American Association of Clinical Endocrinologists, and the American College of Endocrinology have all made major shifts in their algorithms of glucose control for type 2 DM patients. Those studies attempted to achieve ‘glycemic equipoise’ between treatment and control groups, only to find that SGLT2i gave a better glucose control (less HbA1c) than controls. Therefore, the authors concluded that the renal benefits are due to better glucose control. On the other hand, the effect of eGFR on glycemic control is still debatable, as reviewed by Rossing. For example, in that review, overt proteinuria of DKD has long been considered a ‘point of no return’ regarding glycemic control. Renal benefits differ across patients of different background status. A number of limitations should also be pointed out in those studies, for example, the monitoring of renal function based on serum creatinine levels, long-term glucose control using FBS, and small sample sizes. Therefore, the exact association between indicator for long-term glucose control (HbA1c or glycemic variability) and renal function monitor (eGFR rather than serum creatinine) remained elusive. HbA1c presents some weaknesses in long-term glucose evaluation: the requirement of months to determine the marker effect, and glycemic control may be underestimated in the case of anemia or uremia. For this reason, we further set a new marker (HbA1c_CV) to represent glycemic glucose control. In addition, there are many potential confounding factors for the evaluation of eGFR, such as age, gender, value of SBP, ACEi/ARB, and the use of statins. The effects on eGFR of glycemic control needed to be re-evaluated after adjusting for the above confounding factors, just as we have done in this study.

Recently, a new recommendation for TIR goals using a CGM was posted at the 79th Scientific Sessions of the ADA in San Francisco. CGM has benefits for long-term glycemic evaluation and reduces glycemic variability. When linked with artificial intelligence, CGM provides real-time feedback to diabetic patients on modifiable patterns of glycemic excursions. In February 2019, the Advanced Technologies and Treatments for Diabetes Congress launched consensus recommendations for relevant aspects of CGM data.
utilization on various diabetes populations. The importance of long-term glycemic variability is therefore recognized. Despite this, the routine use such invasive monitoring remains limited in clinical practice. Until now, no glycemic variability marker has been established as the gold standard. Self-monitored blood glucose (SMBG)-based evaluation was reported as easy to use without special software to reduce glucose variability. But not every patient would self-perform the SMBG. Therefore, an easily obtainable marker for glycemic variability was in demand. Here, we used HbA1c_CV as this marker because all diabetic patients receive HbA1c checkups regularly. In this study, we found that the higher the variability of glycemic control (i.e. higher HbA1c_CV), the faster the decline in eGFR, regardless of other patient characteristics like age, gender, ACEi/ARB or not, statin use or not, and BP control. Whether baseline CKD or not (eGFR < 60 ml/min/1.73 m²), higher HbA1c_CV was consistently associated with faster renal function deterioration. Even with baseline eGFR < 60 ml/min/1.73 m², patients with aggressive glucose control with low variability of HbA1c still had stable renal function with no decline (annual eGFR decline = −0.21 ml/min/1.73 m², 95% CI = −1.04 to 0.61). In other words, physicians would be better not to stop aggressive glucose control (minimize glycemic variability) even with existing CKD status. Patients with better baseline eGFR (≥ versus < 60 ml/min/1.73 m²) had faster eGFR decline (against their corresponding glycemic variability controls). These results suggested that physicians should aim to minimize glycemic variability as early as possible to stop renal function deterioration, especially in patient groups with high eGFR (≥60 ml/min/1.73 m²).

Similarly, poor baseline glucose control had faster renal function decline. When not achieving the standard HbA1c goal (%) (A1c ≥ 7), renal function always declined, even with minimal glycemic variability. This result is consistent with previous studies, supporting the view that better control of HbA1c is associated with smaller eGFR declines.
On the contrary, if patients had best glucose control, their renal function would not deteriorate. Therefore, for those achieving the standard HbA1c goal, their eGFR might still decline if they still had high glucose variability. They should keep achieving and maintaining not only their HbA1c goal but also low HbA1c_CV.

UAE is an important monitor of long-term renal function deterioration. Before reaching macroalbuminuria (stage 4 DKD), aggressive suppression of glycemic variability stopped eGFR decline. But once reaching the stage of macroalbuminuria (UAE ≥ 300 mg/g), minimizing HbA1c_CV produced no renal benefits. The so-called ‘point of no return’ applied also to our present study. Results of eGFR-subgroup analysis are also consistent with the idea that minimizing glycemic variability as early as possible stops eGFR decline. Besides, even in patients with very early DKD (normoalbuminuria, UAE < 30), higher HbA1c_CV fit the trend of more eGFR decline in our study. This finding is consistent with a recent study showing that the occurrence of a significant drop of eGFR in both type 1 and type 2 DM individuals, even in the presence of normoalbuminuria. All these studies point out the importance of minimizing glucose variability.

A recent study reported that high glucose variability was associated with the development of albuminuria (upper quartile hazard ratio = 1.3; 95% CI = 1.1–1.6), rather than eGFR decline. However, the eGFR decline is significant in patients with higher glucose variability in our study. There are several reasons for this discrepancy. First, the study designs were different. In our study, we focused only on the effect of glucose variability on eGFR decline, whereas, the study of Ceriello and colleagues researched more parameters. More importantly, there were different cohort baseline characteristics. The baseline glucose control was worse in the present study (HbA1c = 8.0%) than in the study of Ceriello and colleagues (HbA1c = 7.1%). The mean duration of diabetes was longer in our study (10 years) than in the Ceriello study (8 years). In addition, the baseline renal function was also worse in our study (eGFR = 63 ml/min/1.732 m²) than in the Ceriello study (eGFR = 87 ml/min/1.732 m²); patients in the latter cohort had better sugar control, shorter duration of diabetes, and less renal dysfunction. Therefore, we can analyze the outcome of eGFR (long-term renal outcome) more easily.

We report here an easily obtained marker (HbA1c_CV) to facilitate the prediction of renal function in clinical practice. Early aggressive glucose control was found to stop eGFR decline, supporting the importance of glycemic variability in the process of eGFR deterioration. High variability of HbA1c may lead to endothelial injuries, even under the situation of low FBS. Glucose excursions likely cause oxidative stress with metabolic memory (legacy effect), which is found to be associated with the AKT signaling pathway in diabetic rats. In another study, glycemic variability is associated with a number of factors that cause endothelial injuries: polyol activity, hexosamine activity, activation of protein kinase C, and generation of advanced glycation end-products. Glucose swings, compared with chronic sustained hyperglycemia, are a more specific trigger of oxidative stress. The legacy metabolic burden could cause DKD even after improvements in glycemic control. A meta-analysis reported that HbA1c variability is independently associated with the progression of renal status in both type 1 and 2 diabetic patients, a finding that is consistent with ours. However, most studies, unlike ours, had not adjusted for potential confounding factors for eGFR decline.

There are some limitations to this study. First, even with more than 1000 patients, still higher case numbers may be needed to adjust for more variables. Second, we found no correlation between HbA1c_CV and CGM. However, in this study, we proved the correlation of HbA1c_CV with renal function. Further studies are necessary to compare different markers of glucose variability. Finally, we did not analyze eGFR decline based on ACEi or ARB usage. We plan to analyze this further in our ongoing study.

**Conclusion**

In addition to standard glycemic control (HbA1c), HbA1c_CV is also an important parameter in long-term prediction of eGFR decline. Even under control of HbA1c (<7), patients with high HbA1c_CV still experienced eGFR decline. Early minimization of glycemic variability (before macroalbuminuria) can stop deterioration of renal function. Regular checking
and minimizing of HbA1c.CV is highly recommended for daily diabetic care.

**Funding**
The authors disclosed receipt of the following financial support for the research, authorship, and publication of this article: This study was supported by grants TCVGH-VHCY1078604, TCVGH-1073604C, TCVGH-T1078808, TCVGH-NCHU1087606, and TCVGH-1087301C from Taichung Veterans General Hospital.

**Conflict of interest statement**
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Informed consent**
This study was approved by Ethics Committee of Taichung Veterans General Hospital, IRB number: CE16235A. We confirm that all patients gave written informed consent.

**ORCID ID**
Shang-Feng Tsai https://orcid.org/0000-0002-6119-0587

**Reference**

1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care* 2004; 27: 1047–1053.

2. Koro CE, Lee BH and Bowlin SJ. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. *Clin Ther* 2009; 31: 2608–2617.

3. Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990-2010. *N Engl J Med* 2014; 370: 1514–1523.

4. Arora MK and Singh UK. Molecular mechanisms in the pathogenesis of diabetic nephropathy: an update. *Vascul Pharmacol* 2013; 58: 259–271.

5. Kamijo-Ikemori A, Sugaya T and Kimura K. Novel urinary biomarkers in early diabetic kidney disease. *Curr Diab Rep* 2014; 14: 513.

6. Mogensen CE, Christensen CK and Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. *Diabetes* 1983; 32(Suppl. 2): 64–78.

7. Tommei J, Smits MM, et al. Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. *J Am Soc Nephrol* 2017; 28: 1023–1039.

8. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med* 2001; 345: 861–869.

9. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med* 2001; 345: 851–860.

10. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med* 2015; 373: 2117–2128.

11. Wiviott SD, Raz I and Sabatine MS. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. Reply. *N Engl J Med* 2019; 380: 1881–1882.

12. Neal B, Perkovic V and Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med* 2017; 377: 2098–2099.

13. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. *N Engl J Med* 2019; 380: 2295–2306.

14. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med* 2016; 375: 311–322.

15. Mann JFE, Orsted DD and Buse JB. Liraglutide and renal outcomes in type 2 diabetes. *N Engl J Med* 2017; 377: 2197–2198.

16. American Diabetes Association. 16. Diabetes advocacy: standards of medical care in diabetes-2019. *Diabetes Care* 2019; 42: S182–S183.

17. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American association of clinical endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2019 executive summary. *Endocr Pract* 2019; 25: 69–100.

18. Cefalu WT, Kaul S, Gerstein HC, et al. Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a diabetes care editors’ expert forum. *Diabetes Care* 2018; 41: 14–31.

19. MacIsaac RJ, Jerums G and Elkenci E. Effects of glycaemic management on diabetic kidney disease. *World J Diabetes* 2017; 8: 172–186.
20. Lee CL, Li TC, Lin SY, et al. Dynamic and dual effects of glycated hemoglobin on estimated glomerular filtration rate in type 2 diabetic outpatients. *Am J Nephrol* 2013; 38: 19–26.

21. Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. *Lancet* 2010; 376: 419–430.

22. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med* 2009; 360: 129–139.

23. The Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the diabetes control and complications trial. *Kidney Int* 1995; 47: 1703–1720.

24. DCCT/EDIC Research Group, de Boer IH, Sun W, et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. *N Engl J Med* 2011; 365: 2366–2376.

25. Bilous R. Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? *Diabet Med* 2008; 25(Suppl. 2): 25–29.

26. Ceriello A, De Cosmo S, Rossi MC, et al. Variability in HbA1c, blood pressure, lipid parameters and serum uric acid, and risk of development of chronic kidney disease in type 2 diabetes. *Diabetes Obes Metab* 2017; 19: 1570–1578.

27. Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. *J Am Soc Nephrol* 2006; 17: 2937–2944.

28. Rigalleau V, Lasseur C, Raffaitin C, et al. Glucose control influences glomerular filtration rate and its prediction in diabetic subjects. *Diabetes Care* 2006; 29: 1491–1495.

29. Teo BW, Xu H, Wang D, et al. GFR estimating equations in a multiethnic Asian population. *Am J Kidney Dis* 2011; 58: 56–63.

30. Hsu CC, Hwang SJ, Wen CP, et al. High prevalence and low awareness of CKD in Taiwan: a study on the relationship between serum creatinine and awareness from a nationally representative survey. *Am J Kidney Dis* 2006; 48: 727–738.

31. Hwang SJ, Yang WC, Lin MY, et al. Impact of the clinical conditions at dialysis initiation on mortality in incident haemodialysis patients: a national cohort study in Taiwan. *Nephrol Dial Transplant* 2010; 25: 2616–2624.